Mohammad Nadeem Khan,
- Researcher Department of Pharmacology (Clinical Pharmacology), Sri Aurobindo Medical College & PG Institute, Sri Aurobindo University, Indore Madhya Pradesh India
Abstract
The COVID-19 pandemic has highlighted the potential impact of hyperglycemia, especially its link to cardiovascular disease (CVD) and endothelial dysfunction. COVID-19 can cause systemic inflammation and endothelial damage, worsening complications related to hyperglycemia. Persistent inflammation and endothelial dysfunction are crucial elements in the progression of atherosclerosis and other cardiovascular diseases. The long-term health effects of COVID-19, known as “Long COVID” or post-acute sequelae of SARS-CoV-2 infection (PASC), have raised concerns about metabolic issues, including glucose metabolism disruption and insulin resistance. The persistent inflammatory response in Long COVID may contribute to insulin resistance, while direct viral effects on metabolic tissues can influence glucose metabolism, predisposing individuals to hyperglycemia. The interplay between COVID-19-induced endothelial dysfunction and hyperglycemia can have synergistic effects, leading to microvascular damage and increased cardiovascular risk. Endothelial injury from SARS-CoV-2, coupled with the oxidative stress induced by hyperglycemia, can perpetuate inflammation and impair vascular function. Microvascular damage increases the risk of thrombosis and organ dysfunction, with implications for long-term cardiovascular health. Effective management of hyperglycemia is crucial in mitigating cardiovascular complications, especially in individuals with pre-existing diabetes. Lifestyle changes, stress management, and maintaining proper blood sugar levels are crucial elements of diabetes management. Regular monitoring of vascular health and adjustments to treatment plans may be necessary, particularly in individuals recovering from COVID-19. Understanding the intricate relationship between hyperglycemia, endothelial dysfunction, and cardiovascular risk in the context of COVID-19 is vital for developing targeted interventions and optimizing long-term health outcomes.
Keywords: Hyperglycemia, Endothelial Dysfunction, Cardiovascular Risk, COVID-19 Long-term, Health Metabolic Disturbances, Inflammation, Atherosclerosis, Thrombosis, Insulin Resistance
[This article belongs to Research & Reviews: A Journal of Medicine(rrjom)]
References
- Gerich JE. The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity. Endocrine reviews. 1998 Aug 1;19(4):491-503.
- Chisholm DJ, Campbell LV, Kraegen EW. PATHOGENESIS OF THE INSULIN RESISTANCE SYNDROME (SYNDROME X) Proceedings of the Australian Physiological and Pharmacological Society Symposium: Diabetes. Clinical and experimental pharmacology and physiology. 1997 Oct;24(9‐10):782-4.
- Muller DC, Elahi D, Tobin JD, Andres R. The effect of age on insulin resistance and secretion: a review. InSeminars in nephrology 1996 Jul 1 (Vol. 16, No. 4, pp. 289-298).
- Dechenes CJ, Verchere CB, Andrikopoulos S, Kahn SE. Human aging is associated with parallel reductions in insulin and amylin release. American Journal of Physiology-Endocrinology and Metabolism. 1998 Nov 1;275(5):E785-91.
- Pimenta W, Korytkowski M, Mitrakou A, Jenssen T, Yki-Jarvinen H, Evron W, Dailey G, Gerich J. Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM: evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative. Jama. 1995 Jun 21;273(23):1855-61.
- Humphriss DB, Stewart MW, Berrish TS, Barriocanal LA, Trajano LR, Ashworth LA, Brown MD, Miller M, Avery PJ, Alberti KG, Walker M. Multiple metabolic abnormalities in normal glucose tolerant relatives of NIDDM families. Diabetologia. 1997 Sep; 40:1185-90.
- Hopkins PN, Hunt SC, Wu LL, Williams GH, Williams RR. Hypertension, dyslipidemia, and insulin resistance: links in a chain or spokes on a wheel? Current opinion in lipidology. 1996 Aug 1;7(4):241-53.
- American Diabetes Association. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003;26(1): S5-20.
- Stern MP. Impaired glucose tolerance: risk factor or diagnostic category. Diabetes Mellitus: A Fundamental and Clinical Text. Philadelphia, Pa: Lippincott-Raven Publishers. 1996:467-74.
- SM H. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA. 1990; 263:733-9.
- Unger RH, Foster DW. Diabetes mellitus. In: Wilson JD, Foster DW, Kronenberg HM, Larsen PR, eds. Williams Textbook of Endocrinology. Philadelphia, Pa: WB Saunders Co; 1998:973–1059.
- Lloyd CE, Kuller LH, Ellis D, Becker DJ, Wing RR, Orchard TJ. Coronary artery disease in IDDM: gender differences in risk factors but not risk. Arteriosclerosis, thrombosis, and vascular biology. 1996 Jun;16(6):720-6.
- Statistics D. National diabetes information clearinghouse. Bethesda, Md: National Institute of Diabetes and Digestive and Kidney Diseases, NIH publication. 1999 Jan:99-326.
Research & Reviews: A Journal of Medicine
| Volume | 14 |
| Issue | 02 |
| Received | April 15, 2024 |
| Accepted | June 26, 2024 |
| Published | August 21, 2024 |